MNDL Bio specializes in the optimization of recombinant protein expression through a data-driven approach that significantly enhances the efficiency of gene expression processes. The company employs advanced computational models and a multidisciplinary strategy tailored to specific host organisms, allowing for comprehensive gene optimization. This includes the fine-tuning of open reading frames (ORFs), regulatory sequences such as promoters and untranslated regions (UTRs), and vectors. By leveraging hundreds of AI and deep learning algorithms, MNDL Bio can achieve up to three times the protein production yield while reducing the cost of the final product by 50% and accelerating the time to market by 20%.

Additionally, MNDL Bio's innovative technologies include the Evolutionary Stability Optimizer (ESO), which identifies and mitigates mutational hotspots in DNA sequences, ensuring stable gene constructs. Their ChimeraUGEM platform allows for unsupervised gene expression modeling across various organisms, adapting gene expression to optimize protein production. The company also focuses on ribosome traffic engineering to improve host cell titer and growth rates, utilizing quantitative modeling techniques to enhance the understanding of mRNA dynamics. Through these cutting-edge technologies, MNDL Bio aims to revolutionize synthetic biology and provide significant advancements in the field of gene expression optimization.

Israel

MNDL Bio is a Synthetic Biology startup aiming to reduce cost and production time of food and biotech applications through advanced computational platforms that optimize gene expression.
Proud winner of the "Coller Startup Competition" for Edition 2023.

MNDL Bio

Company Details